Mesalamine
Brand name: Mesalamine
Rank #149 of 500 drugs by total cost
$109.3M
Total Cost
176,079
Total Claims
$109.3M
Total Cost
7,734
Prescribers
$621
Cost per Claim
14,220
Beneficiaries
300,549
30-Day Fills
$14K
Avg Cost/Provider
23
Avg Claims/Provider
About Mesalamine
Mesalamine (sold as Mesalamine) was prescribed 176,079 times by 7,734 Medicare Part D providers in 2023, costing the program $109.3M. At $621 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 146 | Bupropion Hcl (Bupropion Hcl Sr) | $110.0M | 3,323,724 |
| 147 | Dimethyl Fumarate (Dimethyl Fumarate) | $109.8M | 29,208 |
| 148 | Immun Glob G(Igg)/Gly/Iga 0-50 (Gammaplex) | $109.6M | 7,815 |
| 149 | Mesalamine (Mesalamine) | $109.3M | 176,079 |
| 150 | Axitinib (Inlyta) | $109.1M | 5,937 |
| 151 | Ipratropium/Albuterol Sulfate (Combivent Respimat) | $108.3M | 353,594 |
| 152 | Relugolix (Orgovyx) | $107.3M | 38,821 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology